MAR 27, 2019 2:36 PM PDT

A Role for the Endocannabinoid System in Down Syndrome

WRITTEN BY: Amy Loriaux

Scientists out of Spain led by Dr. Andrés Ozaita revealed last month in their publication in the journal Neurology of Disease that the endocannabinoid system (ECS) may be involved in the pathogenesis of Down syndrome (DS). Their study was the first to implicate the ECS as a possible contributing cause to the cognitive deficits seen in people with DS. The ECS is a biological system made up of receptors, ligands, and enzymes responsible for making and destroying endocannabinoids. It runs throughout the body and is the target of the phytocannabinoids THC and CBD, as well as others.

Photo sourceUnSplash.com

DS is the most common genetic cause of mental disability. It is caused by the total or partial trisomy of chromosome 21 and affects one in every 700-1000 live births. It is most commonly associated with anatomical abnormalities and intellectual disability. However, people with DS are more likely than non-DS people to develop other diseases such as congenital heart defects, leukemia, Alzheimer's disease, and Hirschsprung disease, to name a few. Thus Dr. Ozaita's team's findings may point to a potential therapeutical target for DS patients.

The authors used two reliable mouse models of DS, the segmentally trisomic Ts65Dn model and a transgenic mouse model overexpressing a single gene candidate for DS cognitive phenotypes. With these two models, the researchers used pharmacological methods to decrease the activity of the cannabinoid receptor type 1 (CB1). First, the team found that in the hippocampus, in which DS patients show marked deficits in hippocampal-dependent memory, there is an overexpression of CB1 receptors in their model mice. Even more, this overexpression is limited to excitatory neurons over inhibitory ones. This could change the excitability/inhibition balance of activity in the region. To investigate if this had any consequence on the normal functioning of the hippocampus, they administered the CB1 antagonists rimonabant or a compound called NESS 0327 for seven days.

Photo sourcePixabay.com

After the mice underwent this injection schedule they showed marked improvement in hippocampal-dependent memory tests. Not only that, but the researchers were able to restore synaptic plasticity, and, most interestingly, rescued hippocampal neurogenesis. Neurons within the hippocampus are able to be produced throughout the lifespan and are thought to be very important in memory.

The exact cause for these alterations has remained unknown. The authors of the present research decided to target the ECS because it is very involved in "fine-tuning" these very same processes. Endocannabinoids have been recognized for their role as neuromodulators and in physiological homeostasis. That is, they make sure several bodily processes are in check. If this modulation is out of sorts in the hippocampus in patients with PD, it could explain some of their learning and memory problems.

As far as the authors know, there are no pharmaceutical treatments available to help improve the intellectual capabilities in DS patients, although some pharmacological treatments have been tried (see here for a review). Targeting the CB1 receptor may be a viable treatment to improve DS patient's quality life. Nevertheless, the disease is genetic, and thus we must wait for accessible genetic therapy specifically designed to treat chromosomal mutations. Yet, regardless of treatment choices, we must remember to give those with DS the opportunity to participate in society and grant them the respect that every individual deserves.    

SourcesNeurology of Disease, Handbook of Experimental PharmacologyProgress in the Chemistry of Organic Natural Products, ScienceDaily.com, Journal of Biomedical Science Disease Models and Mechanisms, ACS Chemical NeuroscienceCell Metabolism, Drug Design, Development and Therapy

About the Author
  • I currently work at a small CRO involved in clinical trial management.
You May Also Like
JUN 24, 2021
Health & Medicine
Cannabis Use in Military Vets on the Increase
JUN 24, 2021
Cannabis Use in Military Vets on the Increase
A new study shows an increase in the number of U.S. military veterans using cannabis, although Veteran Affairs doctors s ...
JUN 28, 2021
Cannabis Sciences
Can Smoking Cannabis Cause COPD?
JUN 28, 2021
Can Smoking Cannabis Cause COPD?
Chronic Obstructive Pulmonary Disease (COPD) is an umbrella term for chronic lung conditions including chronic bronchiti ...
JUL 08, 2021
Cannabis Sciences
High-potency Cannabis Impacts Memory, but not Decision-Making
JUL 08, 2021
High-potency Cannabis Impacts Memory, but not Decision-Making
High-potency cannabis products impair memory in various ways, according to new research published in Scientific Rep ...
AUG 18, 2021
Health & Medicine
Half of Americans Have Tried Marijuana
AUG 18, 2021
Half of Americans Have Tried Marijuana
The latest Gallup poll to measure cannabis use across America shows that the percentage of U.S. adults who say they have ...
SEP 09, 2021
Clinical & Molecular DX
A Drug Test for Synthetic Cannabis Use
SEP 09, 2021
A Drug Test for Synthetic Cannabis Use
Designer drugs are synthetic analogs of prohibited substances such as cocaine and LSD made in clandestine laboratories a ...
SEP 30, 2021
Cannabis Sciences
Concerning New Evidence Regarding Cannabis Use During Pregnancy
SEP 30, 2021
Concerning New Evidence Regarding Cannabis Use During Pregnancy
According to data from a National Vital Statistics Report published in March 2021, the percentage of infants born with a ...
Loading Comments...